BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Sutro Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:30 pm Sale | 2024-09-30 | 13G | Sutro Biopharma, Inc. STRO | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,347,946 (Position Closed) | Filing |
| 2023-02-14 11:45 am Purchase | 2022-12-31 | 13G | Sutro Biopharma, Inc. STRO | BIOTECHNOLOGY VALUE FUND L P | 3,347,946 5.800% | 187,530 (+5.93%) | Filing |
| 2022-01-18 5:18 pm Purchase | 2022-01-07 | 13G | Sutro Biopharma, Inc. STRO | BIOTECHNOLOGY VALUE FUND L P | 3,160,416 6.800% | 1,306,254 (+70.45%) | Filing |
| 2021-02-12 4:25 pm Sale | 2020-12-31 | 13G | Sutro Biopharma, Inc. STRO | BIOTECHNOLOGY VALUE FUND L P | 1,854,162 4.100% | -514,230 (-21.71%) | Filing |
| 2020-05-22 5:22 pm Purchase | 2020-05-12 | 13G | Sutro Biopharma, Inc. STRO | BIOTECHNOLOGY VALUE FUND L P | 2,368,392 6.600% | 2,368,392 (New Position) | Filing |